Closest horizons of Hsp70 engagement to manage neurodegeneration.
dc.contributor.author | Venediktov, AA | |
dc.contributor.author | Bushueva, OY | |
dc.contributor.author | Kudryavtseva, VA | |
dc.contributor.author | Kuzmin, EA | |
dc.contributor.author | Moiseeva, AV | |
dc.contributor.author | Baldycheva, A | |
dc.contributor.author | Meglinski, I | |
dc.contributor.author | Piavchenko, GA | |
dc.date.accessioned | 2023-11-29T15:06:30Z | |
dc.date.issued | 2023-09-19 | |
dc.date.updated | 2023-11-29T14:20:28Z | |
dc.description.abstract | Our review seeks to elucidate the current state-of-the-art in studies of 70-kilodalton-weighed heat shock proteins (Hsp70) in neurodegenerative diseases (NDs). The family has already been shown to play a crucial role in pathological aggregation for a wide spectrum of brain pathologies. However, a slender boundary between a big body of fundamental data and its implementation has only recently been crossed. Currently, we are witnessing an anticipated advancement in the domain with dozens of studies published every month. In this review, we briefly summarize scattered results regarding the role of Hsp70 in the most common NDs including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). We also bridge translational studies and clinical trials to portray the output for medical practice. Available options to regulate Hsp70 activity in NDs are outlined, too. | en_GB |
dc.description.sponsorship | Russian Science Foundation | en_GB |
dc.identifier.citation | Vol. 16, article 1230436 | en_GB |
dc.identifier.doi | https://doi.org/10.3389/fnmol.2023.1230436 | |
dc.identifier.grantnumber | 23–25-00448 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/134691 | |
dc.identifier | ORCID: 0000-0002-2616-595X (Baldycheva, Anna) | |
dc.language.iso | en | en_GB |
dc.publisher | Frontiers Media | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/37795273 | en_GB |
dc.rights | © 2023 Venediktov, Bushueva, Kudryavtseva, Kuzmin, Moiseeva, Baldycheva, Meglinski and Piavchenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | en_GB |
dc.subject | Alzheimer’s disease | en_GB |
dc.subject | Hsp70 | en_GB |
dc.subject | amyotrophic lateral sclerosis | en_GB |
dc.subject | neurodegenerative diseases | en_GB |
dc.subject | neuropharmacology | en_GB |
dc.title | Closest horizons of Hsp70 engagement to manage neurodegeneration. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-11-29T15:06:30Z | |
dc.identifier.issn | 1662-5099 | |
exeter.article-number | 1230436 | |
exeter.place-of-publication | Switzerland | |
dc.description | This is the final version. Available on open access from Frontiers Media via the DOI in this record. | en_GB |
dc.identifier.journal | Frontiers in Molecular Neuroscience | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2023-08-18 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2023-09-19 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-11-29T15:02:22Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2023-11-29T15:06:35Z | |
refterms.panel | B | en_GB |
refterms.dateFirstOnline | 2023-09-19 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2023 Venediktov, Bushueva, Kudryavtseva,
Kuzmin, Moiseeva, Baldycheva, Meglinski and
Piavchenko. This is an open-access article
distributed under the terms of the Creative
Commons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.